Publications in collaboration with researchers from Dana–Farber Cancer Institute (16)

2019

  1. CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC

    Cancer Research, Vol. 79, Núm. 17, pp. 4439-4452

2018

  1. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer

    FASEB Journal, Vol. 32, Núm. 12, pp. 7018-7027

2017

  1. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

    Journal of Thoracic Oncology, Vol. 12, Núm. 8, pp. 1268-1279

2016

  1. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer

    Cancer Discovery, Vol. 6, Núm. 9, pp. 1007-1021

2015

  1. Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition

    Cancer Research, Vol. 75, Núm. 20, pp. 4372-4383

2014

  1. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice

    Genes and Development, Vol. 28, Núm. 5, pp. 479-490

  2. Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

    Cancer Cell, Vol. 26, Núm. 6, pp. 909-922

2013

  1. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

    Cancer Discovery, Vol. 3, Núm. 12, pp. 1355-1363

  2. Efficacy of BET bromodomain inhibition in KRAS-mutant non-small cell lung cancer

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6183-6192

  3. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer

    PLoS ONE, Vol. 8, Núm. 11

2012

  1. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer

    Clinical Cancer Research, Vol. 18, Núm. 18, pp. 4973-4985

  2. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 22, pp. 8699-8704

  3. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response

    Cancer Research, Vol. 72, Núm. 22, pp. 5921-5933

2010

  1. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

    Cancer Research, Vol. 70, Núm. 23, pp. 9827-9836

  2. Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors

    Cancer Cell, Vol. 17, Núm. 6, pp. 547-559

2009

  1. HIF2α cooperates with RAS to promote lung tumorigenesis in mice

    Journal of Clinical Investigation, Vol. 119, Núm. 8, pp. 2160-2170